guidelines:
  "1": Adjuvant_chemotherapy_for_colorectal_cancer.v0.0.1
test_cases:
  - id: 01. No input (negative test).
    input:
      "1": {}
    expected_output:
      "1": {}
  - id: 02. TNM stage missing (negative test).
    input:
      "1":
        gt0004|Risk factors: local::at0017|0–1 risk factor|
    expected_output:
      "1": {}
  - id: 03. Risk factors missing (negative test).
    input:
      "1":
        gt0003|TNM stage: local::at0007|T1–2 N0|
    expected_output:
      "1": {}
  - id: 04. Set to Fluoropyrimidine for 6 months.
    input:
      "1":
        gt0003|TNM stage: local::at0009|T3 N0, pMMR/MSS|
        gt0004|Risk factors: local::at0018|≥ 2 risk factors|
    expected_output:
      "1":
        gt0006|Adjuvant kemoterapi: local::at0007|Fluoropyrimidine for 6 months|
  - id: 05. Set to CAPOX for 3 months or FOLFOX for 3 months.
    input:
      "1":
        gt0003|TNM stage: local::at0011|T4 N0, pMMR/MSS|
        gt0004|Risk factors: local::at0018|≥ 2 risk factors|
    expected_output:
      "1":
        gt0006|Adjuvant kemoterapi: local::at0008|CAPOX for 3 months or FOLFOX for 3 months|
  - id: 06.  Set to CAPOX for 3 months or FOLFOX for 3 months with observation.
    input:
      "1":
        gt0003|TNM stage: local::at0010|T4 N0, dMMR/MSI‑high|
        gt0004|Risk factors: local::at0018|≥ 2 risk factors|
    expected_output:
      "1":
        gt0006|Adjuvant kemoterapi: local::at0008|CAPOX for 3 months or FOLFOX for 3 months|
        gt0007|Observation: local::at0011|If combination therapy is not used for any
          reason, fluoropyrimidine monotherapy is used for 6 months, except in
          dMMR/MSI-high stage II–III disease, where combination therapy is
          preferred.|
  - id: 07. Set to CAPOX for 3 months or FOLFOX for 6 months.
    input:
      "1":
        gt0003|TNM stage: local::at0015|Tx N2, dMMR/MSI‑high and pMMR/MSS|
        gt0004|Risk factors: local::at0017|0–1 risk factor|
    expected_output:
      "1":
        gt0006|Adjuvant kemoterapi: local::at0009|CAPOX for 3 months or FOLFOX for 6 months|
  - id: 08. Set to CAPOX for 3 months or FOLFOX for 6 months with observation.
    input:
      "1":
        gt0003|TNM stage: local::at0013|T3 N1, dMMR/MSI‑high and pMMR/MSS|
        gt0004|Risk factors: local::at0018|≥ 2 risk factors|
    expected_output:
      "1":
        gt0006|Adjuvant kemoterapi: local::at0009|CAPOX for 3 months or FOLFOX for 6 months|
        gt0007|Observation: local::at0012|Oxaliplatin should be discontinued after 6
          months to avoid persistent neuropathy. Treatment should then continue
          with fluoropyrimidine monotherapy.|
  - id: 09. Set to CAPOX for 3-6 months or FOLFOX for 6 months.
    input:
      "1":
        gt0003|TNM stage: local::at0015|Tx N2, dMMR/MSI‑high and pMMR/MSS|
        gt0004|Risk factors: local::at0018|≥ 2 risk factors|
    expected_output:
      "1":
        gt0006|Adjuvant kemoterapi: local::at0010|CAPOX for 3-6 months or FOLFOX for 6 months|
  - id: 10. Set to Abstain.
    input:
      "1":
        gt0003|TNM stage: local::at0007|T1–2 N0|
        gt0004|Risk factors: local::at0017|0–1 risk factor|
    expected_output:
      "1":
        gt0006|Adjuvant kemoterapi: local::at0006|Abstain|
